TY - JOUR
T1 - Nutraceuticals in Lipid-Lowering Treatment
T2 - A Narrative Review on the Role of Chitosan
AU - Patti, Angelo Maria
AU - Katsiki, Niki
AU - Nikolic, Dragana
AU - Al-Rasadi, Khalid
AU - Rizzo, Manfredi
N1 - Publisher Copyright:
© The Author(s) 2014.
PY - 2015/5/21
Y1 - 2015/5/21
N2 - Lipid-lowering drugs may cause adverse effects and, although lipid targets may be achieved, a substantial residual cardiovascular (CV) risk remains. Treatment with agents mimicking proteins present in the body, such as incretin-based therapies, provided promising results. However, in order to improve lipids and CV risk, lifestyle measures remain important. Some researchers focused on nutraceuticals that may beneficially affect metabolic parameters and minimize CV risk. Chitosan, a dietary fiber, can regulate lipids with benefit on anthropometric parameters. The beneficial properties of dietary supplements (such as green tea extract, prebiotics, plant sterols, and stanols) on plasma lipids, lipoproteins, blood pressure, glucose, and insulin levels and their anti-inflammatory and anti-oxidant effects are documented. However, larger, prospective clinical trials are required to confirm such benefits. Such treatments may be recommended when lipid-lowering drugs are neither indicated nor tolerated as well as in order to achieve therapeutic targets and/or overcome residual CV risk.
AB - Lipid-lowering drugs may cause adverse effects and, although lipid targets may be achieved, a substantial residual cardiovascular (CV) risk remains. Treatment with agents mimicking proteins present in the body, such as incretin-based therapies, provided promising results. However, in order to improve lipids and CV risk, lifestyle measures remain important. Some researchers focused on nutraceuticals that may beneficially affect metabolic parameters and minimize CV risk. Chitosan, a dietary fiber, can regulate lipids with benefit on anthropometric parameters. The beneficial properties of dietary supplements (such as green tea extract, prebiotics, plant sterols, and stanols) on plasma lipids, lipoproteins, blood pressure, glucose, and insulin levels and their anti-inflammatory and anti-oxidant effects are documented. However, larger, prospective clinical trials are required to confirm such benefits. Such treatments may be recommended when lipid-lowering drugs are neither indicated nor tolerated as well as in order to achieve therapeutic targets and/or overcome residual CV risk.
KW - chitosan
KW - dietary supplements
KW - lipids
KW - lipoproteins
KW - nutraceuticals
UR - http://www.scopus.com/inward/record.url?scp=84928027364&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84928027364&partnerID=8YFLogxK
U2 - 10.1177/0003319714542999
DO - 10.1177/0003319714542999
M3 - Review article
C2 - 25037700
AN - SCOPUS:84928027364
SN - 0003-3197
VL - 66
SP - 416
EP - 421
JO - Angiology
JF - Angiology
IS - 5
ER -